Open EyeBeta

A public record of U.S. government and large ownership

Brand

IMBRUVICA

IMBRUVICA is a treatment for certain B-cell malignancies and chronic graft-versus-host disease. Johnson & Johnson's fiscal 2025 Form 10-K says it is developed in collaboration and co-marketed in the United States with Pharmacyclics LLC, an AbbVie company.

PharmaceuticalsHealthcare

Documented stakes

  • Johnson & JohnsonControlling stakeHigh confidence

    Listed as a key product in the Innovative Medicine segment of Johnson & Johnson's Form 10-K for the fiscal year ended December 28, 2025. The filing says many of these medicines were developed in collaboration with partners or licensed from other companies. The filing says IMBRUVICA is developed in collaboration and co-marketed in the United States with Pharmacyclics LLC, an AbbVie company.

    As of Dec 28, 2025. Last checked Sep 22, 2026.